Navigation Links
Par Pharmaceutical Reports Third-Quarter 2007 Results
Date:12/20/2007

ion, respectively. Partially offsetting the increases were lower sales of certain existing products due to competitive pressures, including fluticasone, various amoxicillin products, quinapril, megestrol oral suspension, and doxycycline. Revenues of branded products for the third quarter of 2007 of $24.6 million, an increase of 72.5 percent over the prior year period, were driven by increased sales of Megace(R) ES (megestrol acetate) oral suspension, and fees related to the co-promotion of AndroGel(R).

Par's third-quarter gross margin was 31.2 percent of sales, compared to 31.6 percent in 2006. The Company's gross margin reflects the impact of increased metoprolol succinate ER sales, which have significantly lower gross margin percentages than many of the other products sold by the Company. This impact was offset by increased sales of higher margin products such as propranolol ER and Megace ES, lower inventory write-offs and reduced sales on other lower margin products, including fluticasone.

Research and development (R&D) expenses increased 161.0 percent for the third quarter 2007 compared with the third quarter 2006. The increase was due primarily to costs associated with the in-license of two Phase III products in support of the Company's branded division, Strativa. In July, the Company paid $15 million to BioAlliance Pharma for the US commercialization rights to Loramyc. In August, the Company acquired the North American commercial rights from Hana Biosciences, Inc. ("HANA") for Zensana(TM), at which time the Company made a $5.0 million equity investment in Hana at a contractually agreed premium. Of this amount, $1.2 million representing the premium paid was charged to R&D expense in the quarter. In support of the Company's generic business, Par made a $5.0 million equity investment in IntelliPharmaCeutics Ltd. (IPC), a privately held corporation, to develop and market four controlled release generic drug products. Of this amount, approximately $2.
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 26, 2014 It is said that nothing ... Today, UWDress.com, the famous wedding dress supplier, shows its ... site-wide cocktail gown promotion. , UWDress.com’s navy cocktail gowns ... they come in high fashion styles. Simple dresses in bright ... the occasion; they are specially designed for those who want ...
(Date:12/26/2014)... Plugin and template developers from Pixel Film Studios ... Cut Pro X. , “TransPack Volume 5 gives users the ... an industry professional look” Said Christina Austin, CEO of Pixel ... 5, a new level of professionalism will become the standard.” ... Final Cut Pro X transitions featuring organic animations. Choose from ...
(Date:12/26/2014)... 2014 DW-InductionHeating.com (DaWei Induction Heating Co.) ... and developing, producing and marketing of a series of ... announces their new series of induction brazing equipments ... company, induction brazing refers to the joining ... material and heat. The manager says that there are ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... “Every three months the trends for evening ... dress will be one of the hottest styles in the ... Today, the company releases 26 A-line sweetheart evening dresses, and ... , “We are trying our best to help a ... designs. Along with affordable prices, we provide discounted delivery costs ...
Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2
... Nov. 28 Anthem Blue Cross and Blue,Shield in ... than,$185,000 to support 212 not-for-profit organizations as part of ... and Blue Shield,Foundation will match 50 percent of associate ... "Every day our associates ...
... vaccination for parents of new babies and other household members ... form of whooping cough in young infants, say a group ... , Whooping cough (pertussis) is a distressing infectious disease which ... usually given to infants at two to four months of ...
... Eliminating sugary beverages did not affect overall consumption, study ... new study suggests that cutting sodas and other sugar-sweetened ... on teens, overall consumption of the beverages. , ... contributor to increasing rates of childhood obesity in the ...
... vs. local delivery , , WEDNESDAY, Nov. 26 (HealthDay News) -- ... the same for patients who have general or local anesthesia, ... the findings, they say that doctors and patients should decide ... Blocked neck arteries increase the risk of stroke, and a ...
... LONDON, Nov. 27 To coincide with Staying Alive,s ... International has,announced the appointment of Travis McCoy, lead vocalist ... Foundation,s new 2009 Ambassador. , ... Kelly Rowland (Ambassador,since 2008), Beyonce, Mary J Blige, Justin ...
... used to determine which patients will benefit, researchers say , , ... tell doctors whether people with a certain type of non-Hodgkin ... to a new study. , Three different signatures ... biological activity of a gene -- have been identified in ...
Cached Medicine News:Health News:Anthem Blue Cross and Blue Shield in Maine Associates Pledge More Than $277,500 to Community Organizations 2Health News:Parents of new babies should be considered for a whooping cough booster, say experts 2Health News:School Soda Ban Has Limited Effect 2Health News:Anesthesia Type Won't Influence Neck Artery Surgery Outcomes 2Health News:On Staying Alive's 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador 2Health News:On Staying Alive's 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador 3Health News:On Staying Alive's 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador 4Health News:On Staying Alive's 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador 5Health News:On Staying Alive's 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador 6Health News:Genes May Predict Lymphoma Treatment Outcome 2
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 ... plc (NASDAQ: ENDP ) (TSX: ENL), and ... announced today that they have submitted a New Drug ... U.S. Food and Drug Administration (FDA).  Buprenorphine HCl Buccal ... severe enough to require daily, around-the-clock, long-term opioid treatment ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has ... Glucose Market" report to their offering. ... insight focuses on the developments in the self-monitoring blood ... . Reimbursement analysis and the effects of competitive bidding ... 73 SMBG meters have been performed, based on the ...
(Date:12/22/2014)... and STOCKHOLM , Dec. ... (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that ... of the European Medicines Agency (EMA) has adopted a ... histolyticum) for the treatment of adult men with Peyronie,s ... at least 30 degrees at the start of therapy. ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... 2007 /PRNewswire/ -- Mersana, a,cancer therapeutics company, announced ... product candidate, XMT-1001, will,be presented in two posters ... of Cancer Research (AACR) taking place April,14-18th in ... can be,viewed online at the AACR website at ...
... 13, 2007 - Biogen Idec Inc.,(NASDAQ: BIIB) ... the,Academy of Managed Care Pharmacy's (AMCP) 2007 ... a cost-effective therapy in,multiple sclerosis (MS) when ... comprehensive analysis of medical and pharmacy,costs, the ...
Cached Medicine Technology:Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001,at American Association of Cancer Research Annual Meeting 2New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective,Relative to Other Interferon Therapies for Multiple Sclerosis 2New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective,Relative to Other Interferon Therapies for Multiple Sclerosis 3
These flexible stone retrieval devices are reusable, 3 Fr in diameter, with a working length of either 60 cm or 115 cm...
... The Brasseler USA™ MicroLine™ Small Bone ... of operation while performing under the ... powered system developed for small bone ... Drill, Sagittal Saw (Extended Length Available), ...
... Drill, with hand throttle, 30,000 ... Built-in medium bur guard included, ... bur guards are also available. ... hand throttle (#1940) for use ...
... Electric Micro Drill, without hand ... of torque. Built-in medium bur ... extra-long (#1100-006) bur guards are ... with foot throttle (#6401-000), can ...
Medicine Products: